参考文献/References:
［1］FAITH J J, GURUGE J L, CHARBONNEAU M A, et alThe long-term stability of the human gut microbiota ［J］Science, 2013, 341(6141): 44
［2］CHASE Dana, GOULDER A, ZENHAUSERN F, et al. The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment ［J］. Gynecologic Oncology, 2015, 138(1): 190-200.
［3］SCHWABE R F, JOBIN C. The microbiome and cancer ［J］. Nature Reviews Cancer, 2013, 13(11): 800-812.
［4］XIE Xiaohui, YANG Mengyuan, DING Yiling, et al. Microbial infection, inflammation and epithelial ovarian cancer ［J］. Oncology Letters, 2017, 14(2): 1911-1919.
［5］RICE M S, MURPHY M A, TWOROGER S S. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis ［J］. Journal of Ovarian Research, 2012, 5(1): 13.
［6］BANERJEE S, TIAN Tian, WEI Zhi, et al. The ovarian cancer oncobiome ［J］. Oncotarget, 2017, 8(22): 36225-36245.
［7］WIEGAND K C, SHAH S P, AL-AGHA O M, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas ［J］. New England Journal of Medicine, 2010, 363(16): 1532-1543.
［8］CHANDLER R L, DAMRAUER J S, RAAB J R, et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signaling ［J］. Nature Communications, 2015, 6(1): 6118.
［9］GARCA-CASTILLO V, SANHUEZA Enrique, MCNERNEY E, et al. Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle ［J］. Journal of Medical Microbiology, 2016, 65(12): 1347-1362.
［10］POOLE E M, LEE I M, RIDKER P M, et al. A prospective study of circulating C-reactive protein, interleukin-6, and tumor necrosis factor α receptor 2 levels and risk of ovarian cancer ［J］. American Journal of Epidemiology, 2013, 178(8): 1256-1264.
［11］TRABERT B, PINTO L, HARTGE P, et al. Pre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate,lung,colorectal and ovarian cancer (PLCO) screening trial ［J］. Gynecologic Oncology, 2014, 135(2): 297-304.
［12］RUTKOWSKI M R, STEPHEN T L, SVORONOS N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation ［J］. Cancer Cell, 2015, 27(1): 27-40.
［13］TURNBAUGH P J, HAMADY M, YATSUNENKO T, et al. A core gut microbiome in obese and lean twins ［J］. Nature, 2009, 457(7228): 480-484.
［14］LUNGCHUKIET P, SUN Yuefeng, KASIAPPAN R, et al. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxy vitamin D3 and its receptor ［J］. The Journal of Steroid Biochemistry and Molecular Biology, 2015, 148(4): 138-147.
［15］NIEMAN K M, KENNY H A, PENICKA C V, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth ［J］. Nature Medicine, 2011, 17(11): 1498-1503.
［16］MUNKARAH A, MERT I, CHHINA J, et al. Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence ［J］. Gynecologic Oncology, 2016, 141(1): 72-79.
［17］TEBBE C, CHHINA J, DAR S A, et al. Metformin limits the adipocyte tumor-promoting effect on ovarian cancer ［J］. Oncotarget, 2014, 5(13): 4746-4764.
［18］CHEN C, CHANG Y C, LAN M S, et al. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways ［J］. International Journal of Oncology, 2013, 42(3): 1113-1119.
［19］YANG Jiqiao, TAN Qiuwen, FU Qingyu, et al. Gastrointestinal microbiome and breast cancer: correlations, mechanisms and potential clinical implications ［J］. Breast Cancer (Tokyo, Japan), 2017, 24(2): 220-228.
［20］ZHAN Lei, ZHANG Yu, WANG Wenyan, et al. E2F1: a promising regulator in ovarian carcinoma ［J］. Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, 37(3): 2823-2831.
［21］SPANOGIANNOPOULOS P, BESS E N, CARMODY R N, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism ［J］. Nature Reviews Microbiology, 2016, 14(5): 273-287.
［22］GUI Q-f, LU H-f, ZHANG C-x, et al. Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model ［J］. Genetics and Molecular Research : GMR, 2015, 14(2): 5642-5651.
［23］CHITAPANARUX I, CHITAPANARUX T, TRAISATHIT P, et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients ［J］. Radiation Oncology (London, England), 2010, 5: 31.
［24］LIANG M, PRENDERGAST E, RIMEL B J, et al. Antibiotic use negatively influences survival in epithelial ovarian cancer:a case for studying the microbiome ［J］. Gynecologic Oncology, 2016, 143(1): 204.
［25］VIAUD S, SACCHERI F, MIGNOT G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide ［J］. Science (New York, N.Y.), 2013, 342(6161): 971-976.
［26］DAILLRE R, VTIZOU M, WALDSCHMITT N, et al. Enterococcus hirae and barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects ［J］. Immunity, 2016, 45(4): 931-943.
［27］IIDA N, DZUTSEV A, STEWART C A, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment ［J］. Science (New York, N.Y.), 2013, 342(6161): 967-970.
［28］ABIKO K, MANDAI M, HAMANISHI J, et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction ［J］. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013, 19(6): 1363-1374.
［29］DE FELICE F, MARCHETTI C, PALAIA I, et al. Immunotherapy of ovarian cancer: the role of checkpoint inhibitors ［J］. Journal of Immunology Research, 2015,2015(1):762231-762238.
［30］VTIZOU M, PITT J M, DAILLRE R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota ［J］. Science (New York, N.Y.), 2015, 350(6264): 1079-1084.
相似文献/References:
[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(5):0.
[3]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(5):15.
[4]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(5):59.
[5]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(5):72.
[6]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后
患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with
lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):72.
[7]石亚利,梁华茂*,姚颖.腹腔镜卵巢恶性肿瘤再分期手术临床分析（附38例报道）[J].中国计划生育和妇产科,2018,(3):37.
SHI Ya-li,LIANG Hua-mao*,YAO Ying.Clinical analysis of laparoscopic restaging surgery for ovarian
malignancies (report of 38 cases)[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):37.
[8]叶海琼,秦明丽,傅晓冬*.卵巢癌程序性细胞凋亡因子4的临床意义及对预后的评估[J].中国计划生育和妇产科,2018,(4):58.
YE Hai-qiong,QIN Ming-li,FU Xiao-dong*.Clinical significance and prognostic value of programmed cell death factor 4 in patients with ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):58.
[9]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):62.
[10]吴亚男,李红霞*,孟宪宁,等.子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义[J].中国计划生育和妇产科,2018,(9):32.
WU Ya-nan,LI Hong-xia*,MENG Xian-ning,et al.Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(5):32.